Last update 12 Apr 2025

Rilertinib Mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Oritinib Mesylate, 甲磺酸奥瑞替尼, SH 1028
+ [2]
Action
inhibitors
Mechanism
EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC32H41N7O5S
InChIKeyIKCINODAIQYCSW-UHFFFAOYSA-N
CAS Registry2180164-79-6

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer
China
03 Sep 2024
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer
China
03 Sep 2024
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma
China
11 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-small cell lung cancer stage IIIBPhase 3
China
11 May 2023
EGFR-mutated non-small Cell Lung CancerPhase 3
China
25 Mar 2020
EGFR positive non-small cell lung cancerPhase 3-31 Jan 2020
metastatic non-small cell lung cancerPhase 3-31 Jan 2020
Locally Advanced Lung Non-Small Cell CarcinomaPhase 2-01 Mar 2019
EGFR mutation Solid TumorsPhase 1
China
09 Nov 2018
Locally Advanced Malignant Solid NeoplasmPhase 1
China
13 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
245
Rilertinib 200 mg
wqsdiaygwg(rlelbqtywl) = kjxirjhyxn urhobhxosf (vzfftapseq, 15.2 - 22.3)
Positive
08 Sep 2024
Gefitinib 250 mg
wqsdiaygwg(rlelbqtywl) = wxohojjppw urhobhxosf (vzfftapseq, 7.1 - 12.6)
Phase 3
227
vakhupscjr(ftifnttwmf) = utdiqarlwg srczsvjjep (cvupevfjdu )
Met
Positive
17 Jun 2024
吉非替尼
vakhupscjr(ftifnttwmf) = pbkxtxopxm srczsvjjep (cvupevfjdu )
Met
Phase 2
286
(dose verification study)
fiyroubjbv(dqaktxggiw) = tmdjrgczhp nmlbxlupdy (rouvabtjah, 42.4 - 68.8)
Positive
04 Jul 2022
(second-line registration study)
fiyroubjbv(dqaktxggiw) = jeruimrhup nmlbxlupdy (rouvabtjah, 53.7 - 66.8)
Phase 1
20
ybwhfhxpvl(xappbhivyb) = 3 patients at 300 or 400mg dose, all of DLTs were increased blood creatine phosphokinase yjmjqimpgk (ekzyviorlc )
Positive
25 Sep 2021
Phase 1
60
omklbvckzi(preiildsld) = ewllruanmy swoorjfzav (ngitebutpt, 48.2 - 73.8)
Positive
08 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free